icon-account icon-glass
FREE Podcast Series with Medical Advisor Dr. Bill Code
Connect

Escitalopram WITHDRAWAL

Escitalopram Withdrawal and Tapering Help

Call us for Cipralex withdrawal treatment   

Looking for help to Come Off Escitalopram?  Quitting Escitalopram can seem daunting but our nonprofit has helped people in 78 countries over the last 15 years and we take a holistic, natural approach to controlling Escitalopram Withdrawal Symptoms. Escitalopram is marketed under the brand names Cipralex and Lexapro, approved by the FDA in 2002 for the treatment of generalized anxiety and major depression.  Escitalopram Side Effects can include insomnia, depression, anxiety, nausea, sexual dysfunction and severe lethargy.  Escitalopram Withdrawal Symptoms are common and can cause akathisia, insomnia, anxiety, dizziness, brain zaps and other debilitating symptoms. Quitting Escitalopram must be done slowly.  A gentle Wean off Escitalopram minimizes the symptoms yet many find that Quitting Escitalopram even slowly produces too many symptoms and they want relief.  If you need Help to Stop Escitalopram Contact our experts. We can help you finally Quit Escitalopram naturally.

read more...

SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW

START OUR ESCITALOPRAM WITHDRAWAL PROGRAM

LEARN MORE ABOUT OUR IN-HOME WITHDRAWAL PROGRAM

LIVE CHAT

EMAIL

TALK TO A REAL PERSON 866-605-2333 (toll-free)

REACH OUT FORM

 

"After almost 38 years on psychoactive drugs, I am now totally free of them with Point of Return's help! - Holly (ESCITALOPRAM Withdrawal Success Story)

HOW IT WORKS:

escitalopram taper help  

Our Escitalopram weaning program is a slow taper that allows you to safely Get off of Escitalopram under the guidance of our Prescription Experts, your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Escitalopram until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help minimize Escitalopram withdrawal symptoms to improve mental and physical well-being.

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Escitalopram Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Escitalopram alone, work with our Prescription Drug Experts.

Imagine being Free of Cipralex Addiction 

- Proven Withdrawal Program completed In-Home with Expert Guidance

- Slowly Wean off Escitalopram

- All-Natural Nutraceuticals to help Ease Escitalopram Withdrawal Symptoms

- Professional information on interactions

- Free Mentoring on our 24/7 private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

      PROVEN RESULTS

      SIMPLE - NATURAL - SAFE - EFFECTIVE

      ESCITALOPRAM WITHDRAWAL SUCCESS STORIES

      Denise - escitalopram Withdrawal Help

      I hope that anyone who is seeking to change their life by stopping these medications finds Point of Return.  Thank you! More...

      Denise (Escitalopram Withdrawal Success Story)

      Bob - Escitalopram Weaning Help

      I just want to say thank you to all of you for helping me at the very worst time of my life.  I can't tell you enough how much I appreciate Point of Return.  I will refer anyone I know. More...

      Bob (Escitalopram Withdrawal Success Story)

      Tom - escitalopram Taper Success Story

      I will forever be grateful for your help and will continue to tell others about your marvelous withdrawal program of prescription drug recover when the opportunity presents itself. More...

      Tom (Escitalopram Withdrawal Success Story)

      Dennis - escitalopram Weaning Help

      Thank you from the bottom of my heart.  Your team members, each one of you, are truly life-savers!!! More...

      Dennis (Escitalopram Withdrawal Success Story)

      Karen - escitalopram Taper Help

      Prayers of thanks for the Point of Return's staff will forever be on my lips! More...

      Karen (Escitalopram Withdrawal Success Story)

      NL - escitalopram Withdrawal Success Story

      May God bless all of you for what you do. More...

      N.L. (Escitalopram Withdrawal Success Story)

      I will be forever grateful to God for leading me to POINT OF RETURN for holding my hand every step of the way!

      —Laura (Escitalopram Withdrawal Success Story)

      REACH OUT

      Message sent, thanks!

      Escitalopram Resource Center

      ESCITALOPRAM  WITHDRAWAL SYMPTOMS, SIDE EFFECTS AND ADVERSE REACTIONS ( link | pdf )


      ESCITALOPRAM  HISTORY AND INFO  ( link | pdf )


      ESCITALOPRAM REFERENCES AND FDA INFO ( link | pdf )

      Escitalopram Info and History

      The primary action of Escitalopram (Lexapro) is on Serotonin. Serotonin influences the cardiovascular, renal, immune and gastrointestinal systems, and is essential to regulate body temperature, heart rate, blood pressure and the sympathetic nervous system. During marketing of Escitalopram (Lexapro) there were spontaneous reports of withdrawal symptoms, particularly when stopping abruptly or rapidly tapering. Reports of serious discontinuation symptoms were also documented. Stopping Escitalopram (Lexapro) incorrectly can adversely affect many areas of the body.

      Lexapro is the brand name for Escitalopram an antidepressant in a group of drugs called Selective Serotonin Reuptake Inhibitors (SSRIs). The mother compound of Escitalopram (Lexapro) is Celexa, which is a mixture of two different isomers (compounds): R-Celexa and S-Celexa, mirror images of each other. But the early studies by Forest Laboratories attributed the effectiveness of Celexa as an antidepressant was due largely to the S-isomer, while many of the side effects were linked to the R-isomer. Escitalopram (Lexapro) became the purified S-isomer of Celexa and required only 3.5 years to develop and was known as a 'cleaner and more potent SSRI."

      Of all the SSRIs currently on the market, Escitalopram (Lexapro)has the highest affinity for the human Serotonin transporter, or the protein that transports Serotonin. This protein is also the target of stimulants drugs such as amphetamines and cocaine.

      The FDA approved Lexapro in 2002 and according to a document released by the U.S. Senate's Special Committee in 2009, Forest Labs was accused of marketing Lexapro for unapproved uses; failing to disclose negative results from the clinical trials; and paying kickbacks to doctors who prescribed the drug. In 2010 Forest Pharmaceuticals agreed to pay $313 million to settle the charges over Escitalopram (Lexapro) and two other Forest drugs (Levothyroid and Celexa). In addition, Escitalopram (Lexapro) has been linked to birth defects and many lawsuits have been filed since the company marketed Escitalopram (Lexapro) as being safe for pregnant women and women of childbearing age. 

      In June 2015 twelve lawsuits were filed against Forest Pharmaceuticals after children were born with birth defects. The plaintiffs claim that Forest knew through pre and post market studies the drug was associated with a significant increased risk of birth defects in babies whose mothers ingested the antidepressants during pregnancy, and despite this knowledge continued to aggressively and actively promote the use by women in child-bearing years.

      Escitalopram Withdrawal Symptoms, Side Effects, Adverse Reactions

      ESCITALOPRAM WITHDRAWAL SYMPTOMS MAY INCLUDE:

      aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression

      ESCITALOPRAM SIDE EFFECTS MAY INCLUDE:

      constipation, decreased appetite, decreased sex drive, diarrhea, dizziness, dry mouth, ejaculation disorder, fatigue, flu-like symptoms, impotence, indigestion, insomnia, nausea, runny nose, sinusitis, sleepiness, sweating, abdominal pain, abnormal dreaming, allergic reactions, blurred vision, bronchitis, chest pain, coughing, earache, fever, gas, heartburn, high blood pressure, hot flushes, increased appetite, irritability, joint pain, lack of concentration, lack of energy, lack of orgasm, light-headedness, menstrual cramps, migraine, muscle pain, nasal congestion, neck and shoulder pain, pain in arms or legs, palpitations, rash, ringing in the ears, sinus congestion, sinus headache, stomachache, tingling, toothache, tremors, urinary problems, vertigo, vomiting, weight changes, yawning

      ESCITALOPRAM ADVERSE REACTIONS MAY INCLUDE: per PDR 

      Severe: pancreatitis, tardive dyskinesia, seizures, suicidal ideation, SIADH, hemolytic anemia, agranulocytosis, GI bleeding, aplastic anemia, heart failure, bradycardia, hypertensive crisis, torsade de pointes, thrombosis, atrial fibrillation, stroke, myocardial infarction, ventricular tachycardia, anaphylactoid reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS, erythema multiforme, angioedema, toxic epidermal necrolysis, Stevens-Johnson syndrome, pulmonary embolism , visual impairment, ocular hypertension, hepatic failure, hepatic necrosis, spontaneous fetal abortion, renal failure (unspecified), rhabdomyolysis, serotonin syndrome, bone fractures, persistent pulmonary hypertension of the newborn, neonatal abstinence syndrome       

      Moderate: ejaculation dysfunction, constipation, impotence (erectile dysfunction), dysphagia , akathisia, choreoathetosis, pseudoparkinsonism, dysarthria, ataxia, migraine, myoclonia, dystonic reaction, nystagmus, amnesia, confusion, delirium, nmania, psychosis, hostilit, impulse control symptoms, hallucinations, depression, hyponatremia, platelet dysfunction, hypoprothrombinemia , anemia, thrombocytopenia, bleeding, leukopenia, hematoma, hypertension, peripheral vasodilation, chest pain (unspecified), phlebitis, QT prolongation, hypotension, orthostatic hypotension, sinus tachycardia, palpitations, edema, dyspnea, blurred vision, hyperbilirubinemia, hepatitis, elevated hepatic enzymes, hyperprolactinemia, priapism, urinary retention, dysuria, myasthenia, hyperglycemia, diabetes mellitus, hypoglycemia, hypokalemia, hypercholesterolemia, osteopenia, withdrawal ,growth inhibition

      Mild: headache, nausea, drowsiness, insomnia, xerostomia, diarrhea, fatigue, libido decrease, hyperhidrosis, dizziness, rhinitis, dyspepsia, vomiting, lethargy, sinusitis, orgasm dysfunction, dental pain, abdominal pain, paresthesias, yawning, menstrual irregularity, flatulence, weight loss, pyrosis (heartburn), gastroesophageal reflux, hypoesthesia, asthenia, nightmare, tremor, vertigo, restless legs syndrome (RLS), emotional lability, irritability, restlessness, agitation, paranoia, anxiety, purpura, epistaxis, ecchymosis, syncope, malaise, fever, rash, photosensitivity, flushing, urticaria, alopecia, cough, nasal congestion, diplopia, mydriasis, tinnitus, dysmenorrhea, menorrhagia, increased urinary frequency, muscle cramps, arthralgia, myalgia, back pain

      ESCITALOPRAM BOXED WARNINGS: per PDR

      Children, growth inhibition, suicidal ideation

      Safety and efficacy have not been established in pediatric populations for any indication except for the treatment of major depressive disorder in children and adolescents 12 years of age and older. There is a causal relationship between the use of antidepressants, such as escitalopram, and the risk of suicidal ideation and behavior in children, adolescents, and young adults (ages 18 to 24 years). The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants (SSRIs and others). The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with SSRIs and other antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in children or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or at the time of dose increase or decrease. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy (i.e., beyond several months). The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder such as obsessive-compulsive disorder (OCD). All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment are considered at an increased risk for suicidal ideation or attempts, and should be closely monitored during treatment with escitalopram. In patients who exhibit changes in symptoms, worsening of depression or emergent suicidality, a decision should be made to change or discontinue treatment. If discontinuing, medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose. The potential for growth inhibition in pediatric patients should be monitored during SSRI therapy. Monitor height and weight periodically while the patient is receiving escitalopram. Data are inadequate to determine whether the chronic use of SSRIs causes long-term growth inhibition; however, decreased weight gain has been observed in children and adolescents receiving escitalopram.

      Escitalopram References and Information

      According to the FDA regarding the discontinuation of Escitalopram, marketed as Lexapro and Cipralex: Discontinuing Lexapro: A gradual dose reduction is recommended (2.4). Discontinuation of Treatment with Lexapro: A gradual reduction in dose rather than abrupt cessation is recommended whenever possible (5.3). 2.4 Discontinuation of Treatment with Lexapro Symptoms associated with discontinuation of Lexapro and other SSRIs and SNRIs have been reported [see Warnings and Precautions (5.3)]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.

      --

      References:

      https://www.medicalnewstoday.com/articles/325620.php

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722507/

      https://www.health.harvard.edu/blog/discontinuation-syndrome-and-antidepressants-2019040416361

      DISCLAIMER:

      *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

      *The statements on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

      * Testimonial results may vary person to person.

      *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with your physician to help you with your drug withdrawal process and with his or her consent.

      *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support. More..